Research Library

The safety and efficacy of many stem cell treatments remain unproven by the FDA, yet state laws promote access and use of these unchecked and potentially harmful treatments. Fellow Kirstin R.W. Matthews summarizes her recent publication in a new commentary — outlining public health consequences of these state laws and calling for scientific societies’ advocacy in state policymaking.

Where do the GOP presidential hopefuls stand on major foreign policy issues? Bonner Means Baker Fellow Joe Barnes explores the Republican candidates’ likely policy approaches to the Ukraine war, Chinese expansionism, fentanyl at the border and more.

Decades of bad policy have heightened the risks of drug use and created barriers to treatment. And while some states are now trying to reduce the harms caused by the drug war, Texas is doubling down on ineffective policies.

The rapid adoption of telemedicine is one of the few positive developments of the COVID-19 pandemic, writes fellow Katharine Neill Harris. She explains why the DEA’s recent proposal to change the rules for prescribing drugs via telemedicine would harm patients and increase demand for and exposure to unregulated and more dangerous drugs.

In 2022, the nation faced fundamental questions about how we govern our economy and society — particularly how we formulate public policy. Here, we share 10 highlights of our work that illustrate our impact from the previous year.

Drug companies that bypass distributors and offer generics directly to patients, like the Mark Cuban Cost Plus Drug Company, could disrupt the pharmaceutical supply chain and ultimately save thousands of lives.

President Andrés Manuel López Obrador’s investment policies, which aim to return Mexico to the protectionist, state-led policies of the 1960s and 1970s, seem almost certain to stagnate the country’s economy.

This October the U.S. and Mexico agreed on a new bilateral security program, but "unless the United States and Mexico pursue domestic structural reforms ... both nations risk backsliding to the failures of the drug wars," writes MGA student and Drug Policy guest contributor Sidney Phillips.

Ten months after the pandemic began, partisan division is severely inhibiting the United States’ COVID-19 response. The health consequences of the continued political divide could not be clearer, as the pandemic has grown beyond many experts’ worst predictions.